Asset profile

SC0062

Small molecule

Preview Research free. Sign in to unlock 3 full asset or company pages every day, no card needed.Sign in to unlock this page
Phase 3underway

Evidence outlook · registrational

Chronic Kidney Disease: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2026-12-31.

How the evidence outlook works ↗

Competitive landscape

61 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 60 same-indication; 25 further along in development.

Unlock with Research ↗
DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
SC0062: this drugPhase 3Small moleculeEndothelin receptor type A (ETA)
SAL0120Phase 2Small moleculeEndothelin receptor type A (ETA)
Atrasentan (Vanrafia)ApprovedSmall moleculeEndothelin A receptor
Avacopan (Tavneos)ApprovedSmall moleculeComplement C5a receptor 1 (C5aR1/CD88)
Baxdrostat (Baxfendy)ApprovedSmall moleculeAldosterone synthase (CYP11B2)
Budesonide (targeted-Release) (TARPEYO / Nefecon)ApprovedSmall moleculeGlucocorticoid receptor
Canagliflozin (Invokana)ApprovedSmall moleculeSGLT2
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2
Daprodustat (Jesduvroq)ApprovedSmall moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)
Difelikefalin (Korsuva)ApprovedPeptideKappa-opioid receptor (agonist, peripherally restricted)
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2
Etelcalcetide (Parsabiv)ApprovedPeptideCalcium-sensing receptor (CaSR), allosteric agonist on parathyroid chief cells
Extended-Release Calcifediol (Rayaldee)ApprovedSmall moleculeVitamin D receptor (VDR), via conversion to calcitriol
Ferric Carboxymaltose (Injectafer / Ferinject)ApprovedIron Complex (iv)Iron repletion
Ferric Derisomaltose (Monoferric / Monofer)ApprovedIron Complex (iv)Iron repletion
Ferric Pyrophosphate Citrate (Triferic)ApprovedSmall moleculeIron-replacement therapy delivered via dialysate

…and 46 more. Research shows the complete landscape.

Research

Unlock the full comparison

Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (1)
December 2026 (1)
Phase 3Chronic Kidney DiseaseRecruiting
Est. primary completion 2026-12-31 · NCT06819826 · CT.gov ↗
What to watch
Unlock with Research ↗
2027 (1)
December 2027 (1)
Phase 2Chronic Kidney DiseaseNot yet recruiting
Est. primary completion 2027-12 · NCT06072326 · CT.gov ↗
What to watch
Unlock with Research ↗

See the full readout calendar ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.